Manufacturing, Packaging & Detailing Market Research Reports & Industry Analysis
Current Good Manufacturing Practices (cGMPs) refers to the regulations enforced by the FDA. The cGMPs provide for systems that assure proper design, monitoring, and control of manufacturing processes and facilities.
Adherence to the cGMP regulations assures the identity, strength, quality, and purity of drug products by requiring that manufacturers of medications adequately control manufacturing operations. This includes establishing strong quality management systems, obtaining appropriate quality raw materials, establishing robust operating procedures, detecting and investigating product quality deviations, and maintaining reliable testing laboratories. This formal system of controls at a pharmaceutical company, if adequately put into practice, helps to prevent instances of contamination, mix-ups, deviations, failures, and errors. This assures that drug products meet their quality standards.
The cGMP requirements were established to be flexible in order to allow each manufacturer to decide individually how to best implement the necessary controls by using scientifically sound design, processing methods, and testing procedures. The flexibility in these regulations allows companies to use modern technologies and innovative approaches to achieve higher quality through continual improvement.
- Use of RFID in serialized unique packaging numbering to authenticate and check for recall/expiry status.
- Use of X-ray and metal detection systems to detect glass, stone, bone, rubber and other contaminants
- Use of checkweighers and sorters
- Use of baggers capable of handling, opening and sealing bags manufactured from specialist sterile films and papers.
- Use of quality control labeling systems
It is important to note that cGMPs are minimum requirements. Many pharmaceutical manufacturers are already implementing comprehensive, modern quality systems and risk management approaches that exceed these minimum standards. This is important because a consumer cannot detect through smell, touch, or sight if a drug product is safe or if it will work.
Manufacturing, Packaging & Detailing Industry Research & Market Reports
-
Global Pharmaceutical Visual Inspection Systems Market - 2025-2033
... the forecast period 2025-2033. Pharmaceutical Visual Inspection Systems Market The pharmaceutical visual inspection systems market is poised for continued growth, with advancements in AI and machine learning leading to more sophisticated and efficient inspection solutions. ... Read More
-
Global Active and Intelligent Packaging in Pharmaceutical Market 2025-2029
... period. The report on the active and intelligent packaging in pharmaceutical market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors. The ... Read More
-
Pharmaceutical Product Manufacturing in Australia - Industry Market Research Report
... has also benefited several participants. However, ongoing challenges including a changing regulatory and risk environment and reform-driven pricing pressures have constrained the industry's growth. Ongoing PBS reforms have heavily influenced manufacturers over the period, as ... Read More
-
Pharmaceutical Chemicals
... CAGR of 4.9% over the analysis period 2024-2030. OTC, one of the segments analyzed in the report, is expected to record a 4.0% CAGR and reach US$16.8 Billion by the end of the analysis period. ... Read More
-
Pharmaceutical Hot Melt Extrusion Equipment
... Million by 2030, growing at a CAGR of 4.3% over the analysis period 2024-2030. Twin Screw Extruders, one of the segments analyzed in the report, is expected to record a 4.1% CAGR and reach US$28.0 ... Read More
-
Pharmerging
... 9.7% over the analysis period 2024-2030. Pharmaceutical, one of the segments analyzed in the report, is expected to record a 8.2% CAGR and reach US$2.1 Billion by the end of the analysis period. Growth in ... Read More
-
Sterile Medical Packaging
... at a CAGR of 7.3% over the analysis period 2024-2030. Plastics, one of the segments analyzed in the report, is expected to record a 8.3% CAGR and reach US$36.5 Billion by the end of the ... Read More
-
Antibiotics
... 3.1% over the analysis period 2024-2030. Penicillin, one of the segments analyzed in the report, is expected to record a 3.3% CAGR and reach US$15.7 Billion by the end of the analysis period. Growth in ... Read More
-
Bioburden Testing
... CAGR of 11.3% over the analysis period 2024-2030. Consumables, one of the segments analyzed in the report, is expected to record a 11.8% CAGR and reach US$1.5 Billion by the end of the analysis period. ... Read More
-
Veterinary Drugs Compounding
... at a CAGR of 7.7% over the analysis period 2024-2030. CNS Agents, one of the segments analyzed in the report, is expected to record a 7.8% CAGR and reach US$1.1 Billion by the end of ... Read More
-
Pharmaceutical Contract Manufacturing
... at a CAGR of 5.2% over the analysis period 2024-2030. Pharmaceutical, one of the segments analyzed in the report, is expected to record a 5.9% CAGR and reach US$93.8 Billion by the end of the ... Read More
-
Alopecia Drugs
... CAGR of 5.5% over the analysis period 2024-2030. Topical, one of the segments analyzed in the report, is expected to record a 5.4% CAGR and reach US$8.4 Billion by the end of the analysis period. ... Read More
-
Ampoules Packaging
... CAGR of 6.2% over the analysis period 2024-2030. Glass, one of the segments analyzed in the report, is expected to record a 6.0% CAGR and reach US$5.6 Billion by the end of the analysis period. ... Read More
-
Angina Pectoris Drugs
... at a CAGR of 4.5% over the analysis period 2024-2030. Beta Blockers, one of the segments analyzed in the report, is expected to record a 4.9% CAGR and reach US$9.6 Billion by the end of ... Read More
-
Antifungal Drugs
... CAGR of 4.2% over the analysis period 2024-2030. Azoles, one of the segments analyzed in the report, is expected to record a 4.5% CAGR and reach US$10.7 Billion by the end of the analysis period. ... Read More
-
Atopic Dermatitis Drugs
... at a CAGR of 21.1% over the analysis period 2024-2030. Biologics, one of the segments analyzed in the report, is expected to record a 22.7% CAGR and reach US$18.7 Billion by the end of the ... Read More
-
Life Sciences BPO
... at a CAGR of 6.5% over the analysis period 2024-2030. Pharmaceutical Outsourcing Services, one of the segments analyzed in the report, is expected to record a 6.4% CAGR and reach US$281.8 Billion by the end ... Read More
-
Lyophilization Equipment and Services
... 2030, growing at a CAGR of 6.8% over the analysis period 2024-2030. Tray Lyophilizers, one of the segments analyzed in the report, is expected to record a 6.3% CAGR and reach US$5.0 Billion by the ... Read More
-
Dosing Systems
... CAGR of 4.6% over the analysis period 2024-2030. Water & wastewater treatment, one of the segments analyzed in the report, is expected to record a 5.6% CAGR and reach US$3.4 Billion by the end of ... Read More
-
Healthcare Cold Chain Logistics
... 2030, growing at a CAGR of 3.9% over the analysis period 2024-2030. Vaccines, one of the segments analyzed in the report, is expected to record a 3.6% CAGR and reach US$11.1 Billion by the end ... Read More
-
Oral Antivirals
... CAGR of 1.5% over the analysis period 2024-2030. Human Immunodeficiency Virus, one of the segments analyzed in the report, is expected to record a 1.0% CAGR and reach US$18.0 Billion by the end of the ... Read More
-
Myelodysplastic Syndrome (MDS) Drugs
... 2030, growing at a CAGR of 9.3% over the analysis period 2024-2030. Immunomodulatory Drugs, one of the segments analyzed in the report, is expected to record a 9.5% CAGR and reach US$2.7 Billion by the ... Read More
-
Nanocapsules
... 6.3% over the analysis period 2024-2030. Oncology, one of the segments analyzed in the report, is expected to record a 7.1% CAGR and reach US$2.0 Billion by the end of the analysis period. Growth in ... Read More
-
Personalized Nutrition
... CAGR of 13.5% over the analysis period 2024-2030. Active Measurement, one of the segments analyzed in the report, is expected to record a 14.5% CAGR and reach US$27.5 Billion by the end of the analysis ... Read More
-
Pharmaceutical Membrane Filtration
... at a CAGR of 10.5% over the analysis period 2024-2030. Filters, one of the segments analyzed in the report, is expected to record a 9.9% CAGR and reach US$11.7 Billion by the end of the ... Read More
Research Assistance
